DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company
focused on novel treatments for Type 2 diabetes today is pleased to announce
results of a proof-of-concept phase IIa trial for DM-99, the company's third
drug in clinical development.


The single dose, placebo controlled, single-blind, crossover trial studying 40
patients with type 2 diabetes examined the effect of DM-99 or placebo treatment
on plasma glucose and insulin levels after a meal tolerance test. Those patients
receiving oral anti-diabetes medications used to stabilize glucose levels
continued treatment during the study. During statistical analysis a sequence
effect between period 1 and period 2 was observed in this crossover study
leaving overall results inconclusive. The underlying cause of this effect is
under investigation. Consistent with standard crossover study design upon
detection of a sequence effect, the statistical analysis plan was predefined to
revert to period 1 results where 20 subjects receiving DM-99 and 20 subjects
receiving placebo were both trial and treatment naive.


The trial was powered to demonstrate a therapeutically significant effect
defined as a p less than 0.2 with an absolute decrease of at least 10% in
glucose and/or insulin. Patients receiving DM-99 in Period 1 showed a decrease
in baseline adjusted peak blood glucose concentration of 19% (p equals 0.077)
versus those receiving placebo. Patients receiving DM-99 in Period 1 showed a
decrease in incremental glucose Area Under the Curve (AUC) 0-240 minutes of 31%
(p equals 0.030) versus those receiving placebo. DM-99 was safe and well
tolerated with only one report of mild nausea that was considered unlikely
related to treatment.


"We are encouraged by the result from this exploratory clinical study along with
the results of prior DM-99 pre-clinical data. Our goal was to see a positive
trend indicated by changes in blood glucose in type 2 diabetes patients after
they have consumed a meal", stated Reggie Bowerman, President & CEO, DiaMedica
Inc. "We believe the results from this proof-of-concept trial support our
continued development of the DM-99 program."


About DiaMedica

DiaMedica is developing novel treatments for type 2 diabetes based on a newly
discovered 'nerve reflex' mechanism for which the Company has been issued two
U.S. patents. DiaMedica completed a successful phase II trial with its lead
product, DM-71, which demonstrated the ability to reduce HbA1c (blood sugar)
levels and weight in humans. DiaMedica also completed a successful phase II
trial with its second compound, DM-83, designed to measure changes in insulin
and glucose. The success of this clinical trial was highly significant as
DiaMedica believes it validates the novel 'nerve reflex' mechanism that would
designate the Company's drugs as first-in-class. Preclinical results from
Vanderbilt University have shown that DM-99 is able to cause tissue to increase
its uptake of glucose from the blood by over 40% (p less than 0.001) during the
first 60 minutes of treatment. DiaMedica has been recognized as one of the Top
Ten(TM) Life Science companies in Canada for the past two years by the Ottawa
Centre for Research and Innovation.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: DiaMedica's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in DiaMedica's filings with Canadian securities regulatory
authorities, as well as DiaMedica's ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form prospectus dated
March 12, 2007. DiaMedica cautions that the foregoing list of important factors
that may affect future results is not exhaustive. When relying on DiaMedica's
forward-looking statements to make decisions with respect to DiaMedica,
investors and others should carefully consider the foregoing factors and other
uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, DiaMedica
cannot provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to update or
revise any forward-looking statement.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024